Hemolytic-Uremic-Like Syndrome Following Polycarboxylate Interferon Induction: Treatment of Dawson's Inclusion-Body Encephalitis

Thomas J. Leavitt, Thomas C. Merigan, John M. Freeman

Research output: Contribution to journalArticle

Abstract

Interferon induction by administration of pyran copolymer was utilized in three patients in an attempt to treat chronic measles encephalitis (Dawson's encephalitis). Although the course of the disease was not effected by interferon induction, administration of the drug produced hematologic and urinary alterations resembling the hemolytic-uremic syndrome in one patient. Hematologic studies in two additional patients documented the heparin-like nature of pyran copolymer, and the production of a late hypercoagulable state following its administration.

Original languageEnglish (US)
Pages (from-to)43-47
Number of pages5
JournalAmerican Journal of Diseases of Children
Volume121
Issue number1
DOIs
StatePublished - 1971

Fingerprint

Hemolytic-Uremic Syndrome
Inclusion Bodies
Pyran Copolymer
Encephalitis
Interferons
Measles
Heparin
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Hemolytic-Uremic-Like Syndrome Following Polycarboxylate Interferon Induction : Treatment of Dawson's Inclusion-Body Encephalitis. / Leavitt, Thomas J.; Merigan, Thomas C.; Freeman, John M.

In: American Journal of Diseases of Children, Vol. 121, No. 1, 1971, p. 43-47.

Research output: Contribution to journalArticle

@article{1cbc8fcc70a44cdbb94e2f3bfe27ea48,
title = "Hemolytic-Uremic-Like Syndrome Following Polycarboxylate Interferon Induction: Treatment of Dawson's Inclusion-Body Encephalitis",
abstract = "Interferon induction by administration of pyran copolymer was utilized in three patients in an attempt to treat chronic measles encephalitis (Dawson's encephalitis). Although the course of the disease was not effected by interferon induction, administration of the drug produced hematologic and urinary alterations resembling the hemolytic-uremic syndrome in one patient. Hematologic studies in two additional patients documented the heparin-like nature of pyran copolymer, and the production of a late hypercoagulable state following its administration.",
author = "Leavitt, {Thomas J.} and Merigan, {Thomas C.} and Freeman, {John M.}",
year = "1971",
doi = "10.1001/archpedi.1971.02100120079010",
language = "English (US)",
volume = "121",
pages = "43--47",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Hemolytic-Uremic-Like Syndrome Following Polycarboxylate Interferon Induction

T2 - Treatment of Dawson's Inclusion-Body Encephalitis

AU - Leavitt, Thomas J.

AU - Merigan, Thomas C.

AU - Freeman, John M.

PY - 1971

Y1 - 1971

N2 - Interferon induction by administration of pyran copolymer was utilized in three patients in an attempt to treat chronic measles encephalitis (Dawson's encephalitis). Although the course of the disease was not effected by interferon induction, administration of the drug produced hematologic and urinary alterations resembling the hemolytic-uremic syndrome in one patient. Hematologic studies in two additional patients documented the heparin-like nature of pyran copolymer, and the production of a late hypercoagulable state following its administration.

AB - Interferon induction by administration of pyran copolymer was utilized in three patients in an attempt to treat chronic measles encephalitis (Dawson's encephalitis). Although the course of the disease was not effected by interferon induction, administration of the drug produced hematologic and urinary alterations resembling the hemolytic-uremic syndrome in one patient. Hematologic studies in two additional patients documented the heparin-like nature of pyran copolymer, and the production of a late hypercoagulable state following its administration.

UR - http://www.scopus.com/inward/record.url?scp=0014973821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0014973821&partnerID=8YFLogxK

U2 - 10.1001/archpedi.1971.02100120079010

DO - 10.1001/archpedi.1971.02100120079010

M3 - Article

C2 - 5539813

AN - SCOPUS:0014973821

VL - 121

SP - 43

EP - 47

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 1

ER -